For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 1,782,300 | 2,214,512.25* | 1,583,879 | 1,677,014 |
| General and administrative | 1,102,538 | 1,234,459.5* | 996,604 | 1,086,865 |
| Total operating expenses | 2,884,838 | 3,448,971.75 | 2,580,483 | 2,763,879 |
| Loss from operations | -2,884,838 | -3,448,971.75* | -2,580,483 | -2,763,879 |
| Other income | - | -250* | - | 125 |
| Foreign currency transaction gain | -1,516 | 4,476* | -2,815 | -8,045 |
| Interest income, net | 61,389 | 87,096.5* | 52,351 | 69,823 |
| Total other income | 59,873 | 91,322.5* | 49,536 | 61,903 |
| Net loss before income taxes | - | -3,357,649.25* | - | - |
| Income tax benefit | - | -126,653.75* | - | - |
| Net loss applicable to common stockholders | -2,824,965 | -3,230,995.5 | -2,530,947 | -2,701,976 |
| Basic EPS | -0.28 | -0.406 | -0.58 | -0.82 |
| Diluted EPS | -0.28 | -0.406 | -0.58 | -0.82 |
| Basic Average Shares | 10,164,898 | 7,958,071 | 4,329,649 | 3,278,677 |
| Diluted Average Shares | 10,164,898 | 7,958,071 | 4,329,649 | 3,278,677 |
SOLIGENIX, INC. (SNGX)
SOLIGENIX, INC. (SNGX)